Which pill best calms stent pain? new study pits four drugs against placebo
NCT ID NCT07447518
First seen Mar 03, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This completed early-phase trial tested four drugs (mirabegron, tamsulosin, solifenacin, and tadalafil) against a placebo to see which best relieves lower urinary tract symptoms caused by double-J stents. Over 500 adults who needed a stent after ureteroscopy or kidney stone surgery took one pill daily. The main goal was to measure symptom improvement using a standard questionnaire.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWER URINARY TRACT SYMPTOMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Elsayed Abdelhalim
Zagazig, 44749, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirabegron, tamsulosin, solifenacin, tadalafil
What this could lead to
If successful, this could identify which drug best reduces discomfort and urinary problems from ureteral stents, improving patient quality of life.
What could go wrong
This is an early-phase trial with a placebo group, so results may not show a clear winner or may have modest benefits. Side effects from the drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.